Screener
Immix Biopharma, Inc. IMMX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $10,414,266 | $9,971,207 |
| Operating lease liability - current | 125,392 | 139,339 |
| Total current liabilities | 10,539,658 | 10,110,546 |
| Operating lease liability – long term | 912,343 | 933,625 |
| Total liabilities | 11,452,001 | 11,044,171 |
| Commitments and contingencies | - | - |
Document
FAQ
- What is Immix Biopharma, Inc.'s operating lease liabilities (current)?
- Immix Biopharma, Inc. (IMMX) reported operating lease liabilities (current) of $125.39K in Q1 2026.
- How has Immix Biopharma, Inc.'s operating lease liabilities (current) changed year-over-year?
- Immix Biopharma, Inc.'s operating lease liabilities (current) increased by 84.9% year-over-year, from $67.82K to $125.39K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Immix Biopharma, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude